Proteomic frailty score

1. Semaglutide improves proteomic frailty score in humans.

   “Proteomic frailty and cardiometabolic disease-risk scores improved during up to 156 weeks of follow-up.”

   Human trialup to 156 weeksn = 10,052

   Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials · Research Square · 22 Sep 2026 · Preprint

Semaglutide →